Generated by AI
iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms. By concentrating on the biotechnology segment, iShares Biotechnology ETF serves as a sector-specific instrument for investors seeking access to one of the most research-intensive areas of the healthcare market. The fund is used by market participants as a way to gain diversified exposure to companies developing innovative medicines and scientific technologies within the healthcare industry.
The latest articles about IBB.
One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.
Fewer holdings, a higher fee, and a shallower drawdown set these two biotech funds apart in ways that could matter for long-term investors.
IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
Smart Beta ETF report for IBB
Summary of Nov 16's posts. Generated by AI.
Summary of Oct 30's posts. Generated by AI.
Summary of Oct 15's posts. Generated by AI.
Summary of Nov 2's posts. Generated by AI.
Investors talking about IBB also mention these. Each card shows that asset’s own numbers for the past 24 hours.